Clinical Trials Browser

Phase 3 × nimotuzumab × Clear all

NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT01345084 2025-03-28

NICAP

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

NCT02395016 2024-04-04

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Phase 3 Completed

90 enrolled 18 charts

Gastrointestinal

Pancreatic Neoplasms

NCT06343116 2024-04-02

NOTABLE-308

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT00957086 2024-01-09

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Phase 3 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05772208 2023-03-16

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT03837808 2022-11-07

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Phase 3 Unknown

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT03413579 2021-08-25

CIMAHOPE

Phase 3 Completed

Uterine Cervical Neoplasms, Neoplasms

NCT01813253 2018-03-26

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms

NCT01074021 2015-10-30

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Phase 3 Unknown

Nasopharyngeal Neoplasms